

ISV ANNUAL CONGRESS 2026 — ORAL PROGRAM

MONDAY, 12 OCTOBER 2026

09:00-10:00	REGISTRATION & WELCOME COFFEE (SPONSORED BY EuBiologics)	Atrium
10:00-10:10	OPENING SESSION	Okapi 1,2,3
	WELCOME BY ISV PRESIDENT: Manon Cox, NextWaveBio, USA CO-CHAIR REMARKS: Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA Lakshmi Krishnan, National Research Council (NRC), Canada Isabel Leroux-Roels, University of Ghent, Belgium	
10:10-10:55	STANLEY PLOTKIN LECTURE	Okapi 1,2,3
	Session Chair: Manon Cox, NextWave Bio, USA / ISV President Yellow fever 17D live attenuated vaccine: A great vaccine but how does it work? Alan Barrett, The University of Texas Medical Branch (UTMB), USA	
10:55-12:15	PLENARY SESSION 1: Population Impact of Vaccination	Okapi 1,2,3
	Session Chairs: Sarah Gilbert, University of Oxford, United Kingdom and Joon Haeng Rhee, Chonnam National University Medical School, South Korea	
10:55-11:20	Clinical Data for the RSVpreF Vaccine in Older Adults, At-Risk Adults Aged 18-59, and Immunocompromised Adults Kumar Ilangovan, Pfizer Vaccine R & D, USA	
11:20-11:45	Rotavirus Vaccines: Where We Are and What's Next Michelle Groome, University of Witwatersrand, South Africa	
11:45-12:00	Recombinant Staphylococcus Aureus Vaccine demonstrating 73.25% Protective Efficacy in Phase III clinical study Jingxin Li, Chengdu Olymvax Biopharmaceuticals Inc, People's Republic of China	
12:00-12:15	Safety and Immunogenicity of a Novel Trivalent Virus-Like Particle Poliovirus Vaccine (VPV): A Phase 1, Randomized, Observer-Blind Trial Qiaolin Yan, CanSino Biologics Inc., People's Republic of China	
12:15-13:30	LUNCH (SPONSORED BY SANOFI)	Atrium
12:30-13:30	SANOFI WORKSHOP Defining Immune Evidence Standards for Respiratory Vaccine Development Session Chair and Moderator: Nnenna Chime, Vaccines R & D, Sanofi, France Panelist: François Beckers, Sanofi Vaccines, France	Gorilla 1
13:30-15:05	PLENARY SESSION 2: Mucosal Vaccines	Okapi 1,2,3
	Session Chairs: Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA and Sandra Depelsenaire, Vaxxas, Australia	
13:30-13:55	Trans-kingdom Effects on Immunity to Viruses Michael S. Diamond, Washington University School of Medicine, USA	
13:55-14:20	Adjuvants - The Tool to Obtain the Required Immune Responses in Vaccination Dennis Christensen, CRODA Pharma, Denmark	
14:20-14:35	Charting Mucosal Immune Responses to Influenza using Human Immune-competent Organoids Martin Beukema, University Medical Center Groningen, The Netherlands	
14:35-14:50	Environmental drivers of oral typhoid vaccine responses in Uganda: dissecting rural–urban differences and the role of Schistosoma mansoni Bridgious Walusimbi, MRC/UVRI and LSHTM Uganda Research Unit, Uganda	
14:50-15:05	Inhaled aerosol vaccination with an adenoviral-vectored TB vaccine induces robust respiratory mucosal immunity in humans Sam Afkhami, McMaster University, Canada	
15:05-15:30	COFFEE BREAK (SPONSORED BY VisMederi)	Atrium

15:30-17:35	CONCURRENT SESSION 1	CONCURRENT SESSION 2	CONCURRENT SESSION 3
	<i>Okapi 1,2,3</i>	<i>Gorilla 1</i>	<i>Gorilla 3</i>
	Adjuvants Session Chairs: Ed Lavelle , <i>Trinity College, Dublin</i> Lars Frelin , <i>Karolinska Institutet, Sweden</i>	Vaccine Regulatory Science and Policy Session Chairs: Manon Cox , <i>NextWave Bio, USA / ISV President</i> Xuefei Zhou , <i>XZ GMP Consulting, USA</i>	“Bright Sparks” in Vaccinology PhD Student Session Session Chairs: Jeffrey Ulmer , <i>TechImmune LLC, USA</i> Martin Beukema , <i>University Medical Center Groningen, Netherlands</i> Alejandra Capozzo , <i>Universidad Abierta Interamericana, Buenos Aires, Argentina</i>
15:30-15:55	Open-access Adjuvants for Prophylactic Human Vaccines Marcelle Van Mechelen , <i>Vaccine Formulation Institute, Switzerland</i>	Regulatory Acceptance of Immunological Biomarkers as Surrogate for Vaccine Efficacy – Ebola Zaire Vaccine Case Marie-Chantal Uwamwezi , <i>PATH, Belgium</i>	Cross-Reactive SARS-CoV-2 Antibodies in Pre-Pandemic Gambian Sera Exhibit Fc-Mediated Effector Activity Dawda Jobe , <i>MRC Unit The Gambia at LSHTM, Gambia</i> <i>(15:30-15:40)</i> Seroepidemiology and serum bactericidal activity of IgG antibodies to Non Typhoidal Salmonella in healthy Children in Mukuru informal settlement in Kenya Schola Kamwethya , <i>Kenya Medical Research Institute, Kenya</i> <i>(15:40-15:50)</i> Switchover Break (15:50-15:55)
15:55-16:20	From Empirical Adjuvants to Programmable Immunity Nathalie Garcon , <i>n3j consulting, Belgium</i>	Beyond Efficacy: How Early Development Decisions Shape the Population Impact of Vaccines Beate Sander , <i>University of Toronto, Canada</i>	The Effect of Malaria Intermittent Preventive Treatment on Vaccine Responses and SARS-CoV-2 Seroprevalence in Adolescents: Findings from a Randomised Controlled Trial Ludoviko Zirimenya , <i>MRC/UVRI & LSHTM Uganda Research Unit, Uganda</i> <i>(15:55-16:05)</i> APC-Mimetic Dendritic Cell-Derived Extracellular Vesicle Nanovaccine with STING Adjuvant Induces Long-Term Th1 Immunity and Immune Memory Against Dengue Virus Anindita Sengupta , <i>Indian Institute of Technology, India</i> <i>(16:05-16:15)</i> Switchover Break (16:15-16:20)
16:20-16:35	Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1 Giang Chau Dang <i>Chonnam National University, South Korea</i>	Primary Healthcare Surveillance and Vaccination Challenges During the 2025 Meningococcal Serogroup C Outbreak Response in Sokoto State, Northern Nigeria Ikechukwu Nnaji , <i>Nigeria Centre for Disease Control and Prevention (NCDC), Nigeria</i>	Induction of influenza-specific immunity in pigs using dissolvable microneedle patches to deliver an adenovirus-based vaccine Inés Co Rives , <i>University College Cork, Ireland</i> <i>(16:20-16:30)</i> Switchover Break (16:30-16:35)
16:35-16:50	Modulation of the bone marrow hematopoietic and immune cell landscape by vaccine adjuvants Eleanor Burgess , <i>Icahn School of Medicine, USA</i>	Immunological assays and correlates of protection: the missing tool for next-generation influenza vaccines Emanuele Montomoli , <i>VisMederi Srl, Italy</i>	Systemic response and short-term functional changes following infection with <i>Necator americanus</i> third-stage infective larvae: Insights from a control human hookworm infection trial in Lambarene, Gabon Therese Vanessa Amana Bokagne , <i>Centre de Recherches Medicales de Lambarene, Gabonese Republic</i> <i>(16:35-16:45)</i> Switchover Break (16:45-16:50)
16:50-17:05	Neutrophils are the dominant early responders to a potent liposomal vaccine adjuvant Lee Sims , <i>University of Oxford, United Kingdom</i>	PANEL DISCUSSION Moderator: Manon Cox , <i>NextWave Bio, USA / ISV President</i> Panelists: Marie-Chantal Uwamwezi , <i>PATH, Belgium</i> Emanuele Montomoli , <i>VisMederi Srl, Italy</i> Beate Sander , <i>University of Toronto, Canada</i> Xuefei Zhou , <i>XZ GMP Consulting, USA</i>	Intranasal protein-based vaccines protect against 2.3.4.4b H5N1 infection in young and old BALB/C mice Gabriel Laghlali , <i>Icahn School of Medicine at Mount Sinai, USA</i> <i>(16:50-17:00)</i> Switchover Break (17:00-17:05)
17:05-17:20	GVX-PA-01, a novel <i>Pseudomonas aeruginosa</i> (Pa) vaccine Elodie Pastural , <i>Glycovax Pharma, Canada</i>		A simplified and sensitive assay for tracking virus-specific T cell responses in the nasal cavity during SARS-CoV-2 human challenge studies <i>(17:05-17:15)</i> Previtha Dawn Sakthi Vale , <i>National University of Singapore, Singapore</i> Switchover Break (17:15-17:20)

17:20-17:35	<i>PIV5-Vectored Intranasal RSV Vaccine is Safe and Immunogenic in Infants and Young Children</i> Biao He, <i>Blue Lake Biotechnology, Inc/CyanVac LLC, USA</i>		AI-Driven Infodemic Surveillance and Its Impact on COVID-19 Vaccine Uptake in Sub-Saharan Africa: A Multi-Country Study Angyiba Serge Andigema, <i>Department of Research, Bisons' Scholars, Douala, Cameroon</i> <i>(17:20-17:30)</i>
17:35-19:00	POSTER SESSION 1 (SPONSORED BY PFIZER)		Atrium
17:35-20:00	WELCOME RECEPTION (SPONSORED BY BHARAT BIOTECH)		Atrium

ISV ANNUAL CONGRESS 2026 — ORAL PROGRAM			
TUESDAY, 13 OCTOBER 2026			
08:00-08:30	WELCOME COFFEE (SPONSORED BY MODERNA)		Atrium
08:30-09:00	KEYNOTE SPEAKER		Okapi 1,2,3
	Session Chair: Michael Schotsaert , Icahn School of Medicine at Mount Sinai, USA		
	From Preclinical Insight to Clinical Evidence: Advancing the Next Generation of Pneumococcal Conjugate Vaccines Annaliesa Anderson , Pfizer, USA		
09:00-10:30	PLENARY SESSION 3: Vaccine Technology		Okapi 1,2,3
	Session Chairs: Indresh Srivastava , Novavax, USA and Linda Lua , The University of Queensland & The Growth Impact, Australia		
09:00-09:25	Beyond the needle - discussing the future of vaccine technologies Tarit Mukhopadhyay , Merck, USA		
09:25-09:50	Advancing Therapeutic Vaccines Through Clinically Validated LNP Delivery Technologies Xiangrong Song , WestGene Biopharma, China		
09:50-10:15	Exploring New Paradigms in Vaccine Landscape Emilio Fumero , Moderna, Spain		
10:15-10:30	Safety, Reactogenicity and Immunogenicity of a Launch-iT Rabies Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Adults Lidia Oostvogels , Astrivax Therapeutics, Belgium		
10:30-11:00	KEYNOTE SPEAKER (VIRTUAL)		Okapi 1,2,3
	Session Chair: Lakshmi Krishnan , National Research Council (NRC), Canada		
	Entering the Vaccine Space During Uncertain Times Peter Marks , Eli Lilly and Company, USA		
11:00-11:20	COFFEE BREAK (SPONSORED BY ARCTURUS THERAPEUTICS)		Atrium
11:20-12:55	CONCURRENT SESSION 4	CONCURRENT SESSION 5	CONCURRENT SESSION 6
	Okapi 1,2,3	Gorilla 1	Gorilla 3
	Immunotherapies	Vaccines for Vector-borne Diseases	“Bright Sparks” in Vaccinology ECR Session
	Session Chairs: Lenny Moise , SeromYx, USA Annie de Groot , EVA Therapeutics, USA	Session Chairs: Kai Dallmeier , KU Leuven, Belgium Alba Grifoni , La Jolla Institute for Immunology, USA	Session Chairs: Barbara Felber , NCI/NIH, USA Valentino D'Onofrio , Ghent University, Belgium Denise Doolan , The University of Queensland, Australia
11:20-11:45	Unleashing our innate immune system as defense against disease Joost Kreijtz Trained Therapeutix Discovery (TTxD), Netherlands	From Efficacy to Impact: What We Can Learn About Dengue Vaccination From TAK-003, a Tetravalent Dengue Vaccine Liudmyla Budovska , Takeda Pharmaceuticals International AG, Switzerland	Effectiveness of PCV10 and PCV13 against invasive pneumonia disease in vietnamese children prior to national introduction: a matched case-control study Cong Hieu Truong , Pasteur Institute in Ho Chi Minh City, Vietnam (11:20-11:30)
			Age-specific immunity gaps and residual susceptibility to measles and rubella before and after the measles-rubella supplementary immunisation campaign in South India Ramya Madhavan , Christian Medical College, India (11:30-11:40)
			Switchover Break (11:40-11:45)
11:45-12:10	Antibody effector functions in antiviral immunity Taia Wang , Stanford University School of Medicine, USA	Controlled human infection studies to accelerate vaccine development Meta Roestenberg , Leiden University, Netherlands	Antigen composition, not T-cell functionality, limits cross-reactivity to distant Coronaviruses after bivalent SARS2 Spike vaccination Ziyin Wang , La Jolla Institute for Immunology, USA (11:45-11:55)

12:10-12:25	In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I-dependent tumor clearance and immune memory Frederic Tangy , <i>Institut Pasteur Oncovita, France</i>	Structural Basis of 4G2-Induced Antibody-Dependent Enhancement in Flaviviruses Camilla Di Giulio , <i>Global Health Institute, EPFL, Switzerland</i>	Implementation Effectiveness of a Community-Driven Vaccination Model at Boosting Immunization in Two Conflict-Affected Health Districts of Cameroon: A Quasi-Experimental Study Derrick Nebangwa , <i>Community-Driven Vaccination Programme (CoVACC), Cameroon</i> (11:55-12:05) <i>Switchover Break</i> (12:05-12:10) Establishing a blood-stage Controlled Human Malaria Infection model in healthy Tanzanian adults with varying prior exposure to P. falciparum Omar Hassan , <i>Ifakara Health Institute, Tanzania</i> (12:10-12:20) <i>Switchover Break</i> (12:20-12:25)
12:25-12:40	Therapeutic HBV vaccine efficacy through ancestral mismatched T cell epitopes Antonio Bertoletti , <i>Duke-NUS Medical School, Singapore</i>	Rational design of live-attenuated West Nile virus vaccines that are non-transmissible by vector mosquitoes Gorben Pijlman , <i>Wageningen University & Research, The Netherlands</i>	An Intranasal Hemagglutinin Protein Booster After Intramuscular mRNA Vaccination Enhances Mucosal Immunity and Confers Protection Against Influenza Virus in Ferrets Seokchan Park , <i>Icahn School of Medicine at Mount Sinai, USA</i> (12:25-12:35) <i>Switchover Break</i> (12:35-12:40)
12:40-12:55	mRNA-Encoded HSV Monoclonal Antibody Based Immunotherapy Outperforms Acyclovir in a Murine Model of HSV-1 Encephalitis Sita Awasthi , <i>University of Pennsylvania, USA</i>	Novel dengue virus non-structural protein vaccine that can prevent disease exacerbation caused by existing vaccines Kyoko Tsukiyama-Kohara , <i>Kagoshima University, Japan</i>	Divergent innate and humoral immune responses to 4CMenB vaccination in transgender individuals receiving gender-affirming hormone therapy Anthony Willems , <i>Ghent University, Belgium</i> (12:40-12:50)
12:55-14:30	LUNCH (SPONSORED BY GPN VACCINES)		<i>Atrium</i>
13:30-14:30	CANADIAN VACCINE R&D SPOTLIGHT (SPONSORED BY THE NRC) Opening Remarks and Canada's Life Sciences and commercialization Lakshmi Krishnan , <i>National Research Council (NRC) Canada</i> Advancing vaccine manufacturing platforms for rapid response to global health emergency Amine Kamen , <i>McGill University</i> Canada's Public Health Agency Canada – From surveillance to vaccine preparedness Celia Lourenco , <i>Public Health Agency Canada</i> Stable CHO pools as a platform for rapid vaccine antigen manufacturing Yves Durocher , <i>National Research Council (NRC) Canada</i>		<i>Gorilla 1</i>
14:00-15:30	POSTER SESSION 2 (SPONSORED BY MERCK)		<i>Atrium</i>
14:30-15:30	ISV ANNUAL GENERAL MEETING		<i>Gorilla 3</i>
15:30-16:00	COFFEE BREAK (SPONSORED BY VAXXAS)		<i>Atrium</i>
16:00-17:35	PLENARY SESSION 4: Systems Vaccinology		<i>Okapi 1,2,3</i>
Session Chairs: Danilo Casimiro, <i>Sanofi Vaccines R & D, USA</i> and Shan Lu, <i>Worcester HIV Vaccine, USA</i>			
16:00-16:25	Complexity from Simplicity: Using Systems Immunology to Define Conserved Innate Immune Mechanisms Mediating Diverse Effector Responses to Vaccines Jeffrey Tomalka , <i>Emory University, USA</i>		
16:25-16:50	Artificial Intelligence and Machine Learning (AI/ML) in the development of mRNA vaccines Fernando Ulloa-Montoya , <i>Sanofi, France</i>		
16:50-17:05	Induction of HIV broadly neutralizing antibodies by human vaccination Isabel Baken , <i>Amsterdam UMC, The Netherlands</i>		
17:05-17:20	Genome-guided identification and validation of novel T-cell vaccine targets for cross-species malaria protection Carla Proietti , <i>The University of Queensland, Australia</i>		
17:20-17:35	Novel DNA Delivery Method Using Lipid Nanoparticles Induces Durable Polyfunctional Immune Responses with Tier2 Neutralizing Antibody and Cytotoxic CD8 T Cells Barbara Felber , <i>NCI/NIH, USA</i>		
17:35-17:50	Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates Name TBC , <i>KU Leuven, Belgium</i>		

18:30-22:00

GALA DINNER (SPONSORED BY FLANDERS)

Marble Hall

ISV ANNUAL CONGRESS 2026 — ORAL PROGRAM			
WEDNESDAY, 14 OCTOBER 2026			
08:00-08:30	WELCOME COFFEE (SPONSORED BY SPYBIOTECH)		Atrium
08:30-09:00	KEYNOTE SPEAKER		Okapi 1,2,3
	Session Chair: Isabel Leroux-Roels , University of Ghent, Belgium From Global Partnerships to Local Impact: Strengthening Vaccine Innovation Laura Palomares , Instituto de Biología UNAM, Mexico		
09:00-10:30	PLENARY SESSION 5: One Health and Pandemic Preparedness		Okapi 1,2,3
	Session Chairs: Albert Osterhaus , University of Veterinary Medicine, Germany and Laura Palomares , Instituto de Biología UNAM, Mexico		
09:00-09:25	Active and Passive Mucosal Immunization Strategies for Improved Pandemic Preparedness Matthew Miller , McMaster University, Canada		
09:25-09:50	Antigenic evolution of H5 viruses and subtype-wide H5 vaccine development Mathilde Richard , Erasmus MC, Netherlands		
9:50-10:05	Safety of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in Tanzanian adults: an open-label, non-randomised phase 1 clinical trial Latipha Mohamed , Ifakara Health Institute, Tanzania		
10:05-10:20	Single-visit rabies vaccination with a simian adenovirus vector elicits durable neutralising antibody responses indicating likely protection for >2 years: mid-term results from the RAB002 phase Ib/II clinical trial Alexander Douglas , University of Oxford, United Kingdom		
10:20-10:35	Design, Development and Characterisation of Multivalent mRNA-LNP Vaccine Candidates for Mpox Hapiloe Maranyane-Tshililo , Afrigen Biologics & Vaccines, South Africa		
10:35-11:00	COFFEE BREAK (CanSino Biologics)		Atrium
11:00-12:35	CONCURRENT SESSION 7 <i>Okapi 1,2,3</i>	CONCURRENT SESSION 8 <i>Gorilla 1</i>	CONCURRENT SESSION 9 <i>Gorilla 3</i>
	Vaccine Confidence Session Chairs: Linda Klavinskis , King's College London, United Kingdom Frederic Tangy , Institut Pasteur Oncovita, France	Emerging Infections Session Chairs: Jeffrey Ulmer , TechImmune LLC, USA Branka Grubor-Bauk , Adelaide University, Australia	Veterinary Vaccines Session Chairs: Amine Kamen , McGill University, Canada Denise Doolan , The University of Queensland, Australia
11:00-11:25	The State of Vaccine Confidence in 2026 Emilie Karafillakis , London Institute for Tropical Medicine and Hygiene, United Kingdom	Preclinical and clinical development of a cellular immunity-based Covid-19 vaccine Helton Santiago , Federal University of Minas Gerais, Brazil	Co-Infections and Immunomodulation: Hurdles and Drivers in Bovine Vaccinology Alejandra Capozzo , Universidad Abierta Interamericana, Buenos Aires, Argentina
11:25-11:50	Beyond Vaccine Hesitancy: Understanding and Rebuilding Trust in Vaccination in Complex Social Ecosystems Ève Dubé , Laval University, Canada	Safety and immunogenicity of EuHZV, an ECLS-based recombinant herpes zoster vaccine: a first-in-human Phase 1 study in adults aged 50–69 years Howard Her , EuBiologics Co., LTD, South Korea	Gamma-SU: A serotype independent Strep. suis vaccine Tim Hirst , GPN Vaccines, Australia
11:50-12:05	Bridging the Mpox Vaccine Uptake Gap in Africa: Determinants of Acceptance and Hesitancy from a Systematic Review and Meta-Analysis Charles Ibeneme , Texila America University Zambia Campus, Zambia	Stabilized henipavirus fusion glycoproteins induce strong serum neutralizing antibody responses against of authentic virus and inform future vaccine design. Haye Nijhuis , Amsterdam UMC, The Netherlands	Selection and characterization of a contemporary respiratory syncytial virus subtype B strain for use in Controlled Human Infection Model (CHIM) studies Albert Osterhaus , University of Veterinary Medicine, Germany
12:05-12:20	PANEL DISCUSSION Moderator: Michael Schotsaert , Icahn School of Medicine at Mount Sinai, USA Panelists:	CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection Lara Kelchtermans , KU Leuven, Belgium	Development of a vaccine against deadly elephant endotheliotropic herpesvirus Xander De Haan , Utrecht University, The Netherlands

12:20-12:35	Emilie Karafillakis , <i>London Institute for Tropical Medicine and Hygiene, United Kingdom</i> Ève Dubé , <i>Laval University, Canada</i> Chunlin Xin , <i>CanSino Biologics, People's Republic of China</i> Igor Smolenov , <i>Arcturus Therapeutics, USA</i>	Characterization of the immune response to <i>Fusobacterium nucleatum</i> , an emerging pathogen associated with adverse pregnancy outcomes Tracy Lee , <i>BC Cancer Research Institute</i>	Evaluation of the protective efficacy of foot-and-mouth disease vaccines against O/CATHAY topotype virus in pigs Yoon Hee Lee , <i>Animal and Plant Quarantine Agency, South Korea</i>
12:35-14:00	LUNCH (SPONSORED BY HUMAN VACCINE IMMUNOTHERAPEUTICS (HVI) AND EXPERT REVIEW OF VACCINES (ERV))		Atrium
13:00-14:00	THE CAREER LAB: MANY PATHS, SHARED PURPOSE <i>An interactive workshop bringing together people across career stages to share experiences, exchange candid advice and lessons learned, and explore your next move towards a meaningful career in the vaccine ecosystem.</i> Linda Lua , <i>The University of Queensland & The Growth Impact, Australia</i>		Gorilla 3
14:00-14:30	AWARD CEREMONY		Okapi 1,2,3
14:30-14:55	ISV PAPER OF THE YEAR (VIRTUAL)		Okapi 1,2,3
	Session Chair: Sita Awasthi , <i>University of Pennsylvania, USA</i>		
	A natural experiment on the effect of herpes zoster vaccination on dementia Pascal Gladsetzer , <i>Stanford University, USA</i>		
14:55-16:10	PLENARY SESSION 6: Challenge Studies		Okapi 1,2,3
	Session Chairs: Isabel Leroux-Roels , <i>University of Ghent, Belgium</i> and Baik-Lin Seong , <i>Yonsei University, South Korea</i>		
14:55-15:20	The Flu Air Shedding and Immune Monitoring (FLAIM) study, the first controlled human infection study at Vaccinopolis, Belgium Joren Raymenants , <i>University of Antwerp, Belgium</i>		
15:20-15:35	Predicting West Nile Virus Outcomes: Insights and Limitations from Murine and Avian Models Byron Martina , <i>Artemis Bioservices., The Netherlands</i>		
15:35-15:50	SARS-CoV-2 humoral waning kinetics are reversed by inactivated vaccine boosting, restoring functional responses, durability and breadth Rafael Medina , <i>Emory University, USA</i>		
15:50-16:00	CLOSING SESSION & INTRODUCTION TO 2027 ISV ANNUAL CONGRESS		Okapi 1,2,3
	Manon Cox , <i>NextWave Bio, USA / ISV President</i> and Lakshmi Krishnan , <i>National Research Council (NRC), Canada</i>		
16:20-17:20	POST CONGRESS – A PANEL DISCUSSION BY BAVARIAN NORDIC New Insights on Mpox: Implications for Public Health and Clinical Practice		Gorilla 3